Reporter Dec 20 2013
Dec. 19, 2013—Editor’s note — the following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2013. Strategic repositioning This year, Vanderbilt University Medical Center proactively embarked on a forward-thinking and necessary mission to reposition the institution to thrive in a fundamentally altered and challenging health care environment. Faced with restricted...
Dec. 19, 2013—VUMC was lauded on numerous national ranking lists during the year.
Dec. 19, 2013—Leadership additions bolstered VUMC’s missions this year.
Dec. 19, 2013—A chemical bond discovered by Vanderbilt University scientists that is essential for animal life and which hastened the “dawn of the animal kingdom” could lead to new therapies for cancer and other diseases.
Dec. 19, 2013—Vanderbilt University researchers have received a two-year, $1.2 million grant from the National Institutes of Health (NIH) to study a mouse model of the metabolic and hormonal changes caused by bariatric surgery.
Dec. 19, 2013—William Stead, M.D., associate vice chancellor for Health Affairs and Chief Strategy Officer at Vanderbilt University Medical Center, has been re-elected to a second full term on the Council of the Institute of Medicine (IOM) of the National Academies.
Dec. 19, 2013—Two features of invasive cancer cells — invadopodia and exosomes — are linked together, Vanderbilt University investigators have discovered.
Dec. 19, 2013—Biomedical and chemical engineers at Vanderbilt University, working with a pathologist, have constructed a sponge-like, biodegradable tissue “scaffold” that releases an enzyme-blocking molecule to indirectly activate endogenous pathways and enhance tissue regeneration and wound healing.
Dec. 19, 2013—Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer.